Introduction
In orthopaedics, the most frequently encountered pathogenic organism is Staphylococcus aureus (Garrod and O'Grady, 1971) . However, anaerobic bacteria can cause osteomyelitis (Finegold and Rosenblatt, 1973; Kelly, Wilkowske and Washington, 1973) and joint infections (Ziment, Davis and Finegold, 1969) . Anaerobic organisms have also been shown to cause infection following total joint replacement (Kramme et al., 1974) .
Among the antibiotics that are available is lincomycin which is effective against both Staph. aureus and the anaerobic organisms which iniclude Bacteroides sp., Clostridium sp. and anaerobic streptococci. Lincomycin has been shown to enter bone in therapeutic levels (Beavis et al., 1975) . A derivative of lincomycin is clindamycin. Clindamycin phosphate being a water-soluble ester of clindamycin and phosphoric acid and has been reported as reaching effective levels in bone (Nicholas et al., 1975; Dornbusch et al., 1977 (Beavis et al., 1975 The supernatant fluid was assayed after extraction and centrifuging.
Results A typical collection of individual data is shown in Fig. 1 . This patient had levels of clindamycin phosphate in bone 4-8 ,ug/ml; capsule of 2-5 [±g/ml; muscle of 11 ,g/ml and fat of 2-3 ,ug/ml, 2-25 hr after the first injection. His serum levels at 1P5 and 3-25 hr were 3 0 and 6-5 ,ug/ml respectively. In bone, clindamycin phosphate achieved therapeutic levels -5 01 jig/ml ± 1P16 (mean ± s.e. mean, N = 11) range 2-4 -15-6 -F±g/ml (Fig. 2) . In the capsule, clindamycin phosphate also achieved therapeutic levels -329,g/ml ± 071 (mean ± s.e. mean, N = 12) range 0 9 -10-4 -,ig/ml (Fig. 2) (1977) measured concentrations of clindamycin in bone in eight patients ranging from 0 4 to 4 9 ,ug/g of bone using an agar diffusion method, both by applying pieces of bone to agar plates and measuring the zone inhibition and by assaying the suspension. For the present cases the latter technique was preferred (Hughes et at., 1975) . (Geddes et al., 1970) . For anaerobes, the MIC is 1 6 jig/ml (Martin, Gardner and Washington, 1972) .
Therefore, there is an effective therapeutic level of clindamycin in the bone and surrounding tissues following parenteral administration.
The place of anaerobic infection in orthopaedics is of great interest. Osteomyelitis is probably caused by anaerobic bacteria much more frequently than is recognized. Accurate bacteriology is needed to isolate the organisms. The anaerobes most commonly isolated are the Gram-negative bacilli and the anaerobic cocci which are effectively treated by clindamycin (Finegold et al., 1972) . Clindamycin has been used in the treatment of osteomyelitis and septic arthritis in children with good results (Feigin et al., 1975) and lincomycin has been successfully applied in the treatment of osteomyelitis in children and adults (McMillan, McRae and McDougall, 1967) .
There were two patients in the present study who developed diarrhoea. Diarrhoea following antibiotics has been well documented (Leading Article, 1975) . The development of the syndrome of pseudomembranous colitis is closely associated, however, with the antibiotics lincomycin, clindamycin and ampicillin, but the pathogenesis is by no means clearly established (Price and Davies, 1977) . Pseudomembranous colitis usually presents as an acute illness, the patient is ill with fever, lower abdominal pain and profuse watery diarrhoea (Cammerer et al., 1976) . Oral clindamycin has been found to produce diarrhoea and pseudomembranous colitis when given to orthopaedic patients as prophylaxis in joint replacement (Smart et al., 1976) . Beavis, Parsons and Jalfield (1976) reviewed the notes of 1158 patients at Guy's Hospital, however, and found three patients with 'colitis', two of whom had had lincomycin and one, clindamycin. On the basis of their review they felt that the continued use of these antibiotics was fully justified for prophylaxis.
There is no doubt, though, that once diarrhoea develops these antibiotics should be stopped (Wells, Cohen and McNeil, 1974) .
The authors conclude that this study has demonstrated that clindamycin phosphate enters bone and surrounding tissues in therapeutic levels following intramuscular and intravenous injections, and can be used for the treatment 
